|
Biomarkers Meeting
|
Meeting/ Workshop
|
BARDA, FDA
|
NIAID
|
Meeting held on June 1st, 2020 provided an overviewon biomarkers in general and the state of the research specific to radiation countermeasures and biodosimetry and to understand the developmental challenges unique to their role in these areas. Participants identified gaps, challenges and needs for translational application with regard to special populations. Subject matter experts and researchers in the field of biomarkers, radiobiology, and biodosimetry discussed complexity of identifying and utilizing biomarkers for triage, biodosimetry, and radiation countermeasures.
|
|
Biomarkers of Exposure and Effect in Agriculture (BEEA)
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) are collaborating to characterize exposure to permethrin and other pesticides by measuring urinary metabolites among participants in the Biomarkers of Exposure and Effect in Agriculture (BEEA) study.
|
|
Bioresource Development, Validation Tools, and Integrating High-Throughput Screening Technology Standards in Complementary and Alternative Medicine (CAM) Product Use in Children
|
Research Initiative
|
CDC, HRSA, SAMHSA
|
NCCIH, NICHD
|
Collaborative efforts between the Food and Drug Administration (FDA) and National Institutes of Health (NIH) for substantiating health benefit claims for probiotics under Investigational New Drug Applications (IND) were placed in the framework of U01 Cooperative Agreements that began in 2008. The successful evaluation of the initiative has recently developed into an invitation to develop a Memorandum of Understanding (MoU) to promote resource sharing and exchange of research expertise; development of demonstration project(s); and the initiation of trans-agency research initiatives focused on the integration of advanced molecular technologies that lead to harmonization standards and improved diagnostics for safety and substantiation of the health benefits of probiotic interventions. In 2011, a collaboration with FDA was initiated to expand the validation tool. In 2012, a Materials Transfer Agreement [MTA] was approved and the FDA received the entire data collection to undergo testing employing their novel microarray multi-loci sequence testing system [MLST].
|
|
Blood Products Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
CC, NHLBI
|
The Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility. The committee also advises the Commissioner of Food and Drugs of its findings.
|
|
Blood, Organ, and Tissue Safety Committee (BOTSEC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA, OS
|
CC, NHLBI
|
The Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is an advisory forum for senior leadership from the Department of Health and Human Services (HHS) organizational components, as well as liaison representatives from Department of Defense and Veterans’ Health Administration, that are involved in blood, organ, and tissue safety and availability. The Department of Health and Human Services (HHS) Assistant Secretary for Health serves as the Council Chair, and the Office of the Assistant Secretary of Health (OASH) Senior Advisor for Blood and Tissue Policy serves as the BOTSEC Executive Director.
|
|
Blood, Organ, and Tissue Senior Executive Council (BOTSEC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, OS
|
NIAID, CC
|
The Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is an advisory forum for senior leadership from the Department of Health and Human Services (HHS) organizational components, as well as liaison representatives from Department of Defense and Veterans’ Health Administration, that are involved in blood, organ, and tissue safety and availability. The HHS Assistant Secretary for Health serves as the Council Chair, and the OASH Senior Advisor for Blood and Tissue Policy serves as the BOTSEC Executive Director.
|
|
Board of Scientific Counselors (BSC) of the CDC''s National Center for Injury Prevention and Control
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, CDC, HRSA, IHS, SAMHSA
|
NICHD, NIA, NIDA, NIMH
|
The BSC advises the Secretary, Department of Health and Human Services; the Director, Centers for Disease Control and Prevention (CDC); and the Director, National Center for Injury Prevention and Control (NCIPC) regarding surveillance, basic epidemiologic research, intervention research, and implementation, dissemination, and evaluation of promising and evidence-based strategies for the prevention of injury and violence. The Board makes recommendations regarding policies, strategies, objectives, projects, and priorities, and reviews progress toward injury and violence prevention.
|
|
Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD
|
The Committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drug products for use in the practice of osteoporosis and metabolic bone disease, obstetrics, gynecology, urology and related specialties, and makes appropriate recommendations to the Commissioner of Food and Drugs.
|
|
Botulism Guidelines Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
CC
|
The National Institutes of Health (NIH) Clinical Center is participating in a working group with the Centers for Disease Control and Prevention (CDC) to develop clinical guidelines for treatment of botulism and use of botulism antitoxin.
|
|
Brain Attack Coalition
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NINDS
|
The Brain Attack Coalition (BAC) is a group of public and private entities representing medical, scientific, advocacy, and government professionals from across the stroke continuum. The BAC is dedicated to setting direction, advancing knowledge, and communicating best practices to improve our ability to prevent and combat stroke.
|